David A. Siegel Genocea Biosciences, Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.01 - $1.38 $100 - $13,799	-10,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.96 - $1.35 $12,169 - $17,113	-12,677 Reduced 55.9%	10,000 $13,000
Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.99 $113,810 - $238,402	-119,800 Reduced 84.08%	22,677 $26,000
Q3 2021 Nov 15, 2021	SELL	$1.74 - $2.33 $184,440 - $246,980	-106,000 Reduced 42.66%	142,477 $274,000
Q2 2021 Aug 16, 2021	SELL	$2.06 - $2.82 $321,360 - $439,920	-156,000 Reduced 38.57%	248,477 $581,000
Q1 2021 May 17, 2021	BUY	$2.35 - $4.01 $455,430 - $777,138	193,800 Added 91.99%	404,477 $1.1 Million
Q4 2020 Feb 16, 2021	BUY	$1.91 - $2.67 $259,760 - $363,120	136,000 Added 182.12%	210,677 $510,000
Q3 2020 Nov 16, 2020	BUY	$1.81 - $5.53 $135,165 - $412,963	74,677 New	74,677 $171,000

10K

Ticker GNCA
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,783,500
Description
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products incl...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.